InVivo touts experimental hydrogel for spinal cord injuries

March 9, 2011 by MassDevice staff

InVivo Therapeutics Holdings Corp. plans to present data on its injectable hydrogel technology for local, controlled-release drug delivery for treatment of spinal cord injury.

NVIV logo

InVivo Therapeutics Holdings Corp. (OTC:NVIV) is headed to Phoenix for the annual meeting of the American Assn. of Neurological Surgeons.

The Cambridge, Mass.-based company plans to present the latest data on its hydrogel for spinal cord injury and neurosurgical applications.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.